Jacobs Levy Equity Management Inc. Sells 642,074 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Jacobs Levy Equity Management Inc. lessened its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 15.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,623,026 shares of the biotechnology company's stock after selling 642,074 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 2.26% of Ironwood Pharmaceuticals worth $16,050,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in IRWD. Journey Strategic Wealth LLC acquired a new position in Ironwood Pharmaceuticals during the 4th quarter worth $45,000. Catalyst Funds Management Pty Ltd acquired a new position in Ironwood Pharmaceuticals during the 4th quarter worth $47,000. Xponance Inc. acquired a new position in Ironwood Pharmaceuticals during the 4th quarter worth $50,000. Envestnet Asset Management Inc. acquired a new position in Ironwood Pharmaceuticals during the 4th quarter worth $50,000. Finally, CIBC Asset Management Inc acquired a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at $53,000.

Wall Street Analyst Weigh In

IRWD has been the subject of several research analyst reports. Leerink Partners cut their price objective on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a report on Monday, April 14th. StockNews.com raised Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Craig Hallum lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 16th. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $1.00 target price (down from $7.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Finally, Jefferies Financial Group reaffirmed a "hold" rating and set a $0.70 target price (down from $8.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Seven research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $4.78.

Ironwood Pharmaceuticals Trading Down 4.1%

IRWD stock traded down $0.02 during mid-day trading on Friday, hitting $0.57. The stock had a trading volume of 5,000,168 shares, compared to its average volume of 2,548,389. Ironwood Pharmaceuticals, Inc. has a 1-year low of $0.53 and a 1-year high of $7.11. The company has a fifty day moving average of $1.07 and a 200 day moving average of $2.53. The stock has a market capitalization of $92.24 million, a price-to-earnings ratio of -19.00 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The business had revenue of $41.14 million for the quarter, compared to the consensus estimate of $67.02 million. As a group, sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.